SAB Biotherapeutics, Inc.

NasdaqCM:SABS Stock Report

Market Cap: US$42.9m

SAB Biotherapeutics Management

Management criteria checks 4/4

SAB Biotherapeutics' CEO is Samuel Reich, appointed in Jan 2024, has a tenure of less than a year. total yearly compensation is $768.40K, comprised of 45.5% salary and 54.5% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth $101.84K. The average tenure of the management team and the board of directors is 2.6 years and 4.5 years respectively.

Key information

Samuel Reich

Chief executive officer

US$768.4k

Total compensation

CEO salary percentage45.5%
CEO tenureless than a year
CEO ownership0.2%
Management average tenure2.6yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

Sep 22
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified

Apr 17
Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified

Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week

Jan 20
Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week

Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues

Nov 19
Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues

Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Nov 18
Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial

Sep 28

What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates

Aug 12
What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates

SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03

Aug 10

Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term

Apr 06
Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term

SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies

Dec 02

CEO Compensation Analysis

How has Samuel Reich's remuneration changed compared to SAB Biotherapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$46m

Jun 30 2024n/an/a

-US$40m

Mar 31 2024n/an/a

-US$40m

Dec 31 2023US$768kUS$350k

-US$42m

Sep 30 2023n/an/a

-US$27m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$985kUS$350k

-US$19m

Sep 30 2022n/an/a

-US$22m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$18m

Dec 31 2021US$3mUS$53k

-US$17m

Compensation vs Market: Samuel's total compensation ($USD768.40K) is about average for companies of similar size in the US market ($USD654.40K).

Compensation vs Earnings: Samuel's compensation has been consistent with company performance over the past year.

CEO

Samuel Reich (49 yo)

less than a year

Tenure

US$768,396

Compensation

Mr. Samuel J. Reich is CEO of SAB Biotherapeutics, Inc. from January 30, 2024 and serves as its Executive Chairman since October 22, 2021 and serves as its Director since November 2020. Samuel J. Reich has...

Leadership Team

NamePositionTenureCompensationOwnership
Samuel Reich
CEO & Executive Chairmanless than a yearUS$768.40k0.24%
$ 101.8k
Eddie Sullivan
Co-Founder10.9yrsUS$807.76k5.67%
$ 2.4m
Christine Hamilton
Co-Founder & Independent Directorno dataUS$25.00k5.63%
$ 2.4m
Christoph Bausch
Executive VP & COO2.6yrsUS$549.32k1.08%
$ 463.8k
Alexandra Kropotova
Executive VP & Chief Medical Officer2.5yrsUS$921.58k0%
$ 0
Edward Hamilton
Co-Founder & Board Observerno datano data3.15%
$ 1.4m
Carlos Carillo
Senior Vice President of Regulatory Affairs3.5yrsno datano data

2.6yrs

Average Tenure

53yo

Average Age

Experienced Management: SABS's management team is considered experienced (2.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Samuel Reich
CEO & Executive Chairman4.1yrsUS$768.40k0.24%
$ 101.8k
Eddie Sullivan
Co-Founderno dataUS$807.76k5.67%
$ 2.4m
Christine Hamilton
Co-Founder & Independent Director10.9yrsUS$25.00k5.63%
$ 2.4m
Edward Hamilton
Co-Founder & Board Observer3.2yrsno data3.15%
$ 1.4m
William Polvino
Independent Director5.9yrsUS$25.00k0%
$ 0
Jeffrey Spragens
Independent Director4.1yrsUS$25.00k0.43%
$ 183.7k
David Link
Independent Vice Chairman6.9yrsUS$25.00k0.062%
$ 26.7k
Erick Lucera
Independent Director1.7yrsUS$26.93k0%
$ 0
Jim Robl
Member of Scientific Advisory Boardno datano datano data
Arturo Casadevall
Member of Scientific Advisory Boardno datano datano data
Michael Haller
Member of the Clinical Advisory Board & Member of Scientific Advisory Boardno datano datano data
Stephen Gitelman
Member of Scientific Advisory Board & Member of Clinical Advisory Board4.9yrsno datano data

4.5yrs

Average Tenure

64yo

Average Age

Experienced Board: SABS's board of directors are considered experienced (4.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 22:33
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SAB Biotherapeutics, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaBrookline Capital Markets
Keay NakaeChardan Capital Markets, LLC
Gum-Ming LoweCraig-Hallum Capital Group LLC